Cost-effectiveness of nasal high-flow in children with acute hypoxaemic respiratory failure

Written By CCRG

Gannon B, Franklin D, Vo V, Babl FE, Schibler A. J Paediatr Child Health. DOI 10.1111/jpc.16558

Aim: A pilot randomised controlled trial assessed the early application of nasal high-flow (NHF) therapy compared with standard oxygen therapy (SOT), in children aged 0 to 16 years presenting to paediatric emergency departments with acute hypoxaemic respiratory failure (AHRF). The study estimated the need to escalate therapy and hospital length of stay in the NHF group compared with SOT. This sub-study then assessed the subsequent cost-effectiveness.

CCRG
Previous

Association between changes in disease severity and physical function after surviving a critical illness
Next

Early myocardial injury in children on doxorubicin for cancer chemotherapy